| pubmed-article:20973869 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20973869 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20973869 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:20973869 | lifeskim:mentions | umls-concept:C0007134 | lld:lifeskim |
| pubmed-article:20973869 | lifeskim:mentions | umls-concept:C0008783 | lld:lifeskim |
| pubmed-article:20973869 | lifeskim:mentions | umls-concept:C1257954 | lld:lifeskim |
| pubmed-article:20973869 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:20973869 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:20973869 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:20973869 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20973869 | pubmed:dateCreated | 2010-12-16 | lld:pubmed |
| pubmed-article:20973869 | pubmed:abstractText | We have recently reported favorable responses to a combination treatment comprising cimetidine, a cyclooxygenase-2 inhibitor and a renin-angiotensin-system inhibitor in metastatic renal cell carcinoma (RCC). In view of the potential synergistic effects of these three agents and interferon-? (I-CCA therapy), we conducted a phase-II trial to examine the efficacy and toxicity of I-CCA as first-line treatment. Fifty-one patients with advanced RCC received natural interferon-? (3-6 million U thrice/week) and cimetidine (800 mg), cyclooxygenase-2 inhibitor meloxicam (10 mg), and renin-angiotensin-system inhibitor candesartan (4 mg) or perindopril (4 mg) orally daily. Memorial Sloan-Kettering Cancer Center prognostic categories were favorable, intermediate and poor in 10 (20%), 31 (61%) and 10 (20%) patients, respectively. The primary end-point was the objective response rate (ORR) and the secondary end-points included clinical benefit, progression-free survival (PFS), overall survival (OS) and safety. Median follow-up was 19 months. Complete response (CR) was observed in four patients (8%) and partial response in seven (14%), yielding an ORR of 22%. None of the four patients who achieved CR relapsed during the 16- to 81-month follow up. The ORR were 17% in the favorable- or intermediate-risk group and 40% in the poor-risk group. The other 24 patients (45%) had stable disease for at least 6 months, resulting in a clinical benefit rate of 67%. The median PFS and OS were 12 and 30 months, respectively. Grade 3/4 toxicities were never observed. The I-CCA therapy, providing favorable responses and low toxicity profiles, is worthy of further consideration as a first-line therapy for metastatic RCC. | lld:pubmed |
| pubmed-article:20973869 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20973869 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20973869 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20973869 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20973869 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20973869 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20973869 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20973869 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20973869 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20973869 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20973869 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20973869 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:20973869 | pubmed:issn | 1349-7006 | lld:pubmed |
| pubmed-article:20973869 | pubmed:author | pubmed-author:MasudaHitoshi... | lld:pubmed |
| pubmed-article:20973869 | pubmed:author | pubmed-author:KiharaKazunor... | lld:pubmed |
| pubmed-article:20973869 | pubmed:author | pubmed-author:SaitoKazutaka... | lld:pubmed |
| pubmed-article:20973869 | pubmed:author | pubmed-author:KawakamiSator... | lld:pubmed |
| pubmed-article:20973869 | pubmed:author | pubmed-author:FujiiYasuhisa... | lld:pubmed |
| pubmed-article:20973869 | pubmed:author | pubmed-author:MatsuokaYohY | lld:pubmed |
| pubmed-article:20973869 | pubmed:author | pubmed-author:KogaFumitakaF | lld:pubmed |
| pubmed-article:20973869 | pubmed:author | pubmed-author:TatokoroManab... | lld:pubmed |
| pubmed-article:20973869 | pubmed:author | pubmed-author:IimuraYasumas... | lld:pubmed |
| pubmed-article:20973869 | pubmed:copyrightInfo | © 2010 Japanese Cancer Association. | lld:pubmed |
| pubmed-article:20973869 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20973869 | pubmed:volume | 102 | lld:pubmed |
| pubmed-article:20973869 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20973869 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20973869 | pubmed:pagination | 137-43 | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:meshHeading | pubmed-meshheading:20973869... | lld:pubmed |
| pubmed-article:20973869 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20973869 | pubmed:articleTitle | Phase-II trial of combination treatment of interferon-?, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. | lld:pubmed |
| pubmed-article:20973869 | pubmed:affiliation | Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. | lld:pubmed |
| pubmed-article:20973869 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20973869 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
